The industry’s leading scalable electroporation technology for high-yield, transient expression of proteins and rapid stable cell line development.
Rapidly transfect from 75 thousand to 20 billion cells
High efficiency enables flexible media strategies that can deliver significant cost savings
Improved yields for decreased development timelines
Proprietary Flow Electroporation™ Technology
Faster production of stable clones
ISO-certified and CE-marked
https://www.americanpharmaceuticalrev...